Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), is a United States Supreme Court case in which the Court held that the pre-emption clause of the Medical Device Amendment bars state common-law claims that challenge the effectiveness or safety of a medical device marketed in a form that received premarket approval from the Food and Drug Administration.

[1] It modified the rule in Medtronic, Inc. v.

Lohr.

This article related to the Supreme Court of the United States is a stub.

You can help Wikipedia by expanding it.